**a.Brown seaweeds**

Among the brown seaweeds, *Ecklonia cava* has been extensively studied for its anti-diabetic activity. The phlorotannins isolated from *Ecklonia cava* such as eckol *Advanced Pharmacological Uses of Marine Algae as an Anti-Diabetic Therapy DOI: http://dx.doi.org/10.5772/intechopen.96807*

(IC50: 1*:*6 × 103 *μ*M), phlorofucofuroeckol-A (IC50: 2*:*4 × 103 *μ*M), fucofuroeckol A (IC50: 7*:*4 × 102 *μ*M), and dieckol (IC50: 7*:*4 × 102 *μ*M) could inhibit the formation of advanced glycation end products comparable to the standard drug aminoguanidine hydrochloride (IC50: 8*:*1 × 103 *μ*M) [60]. Similarly, the phlorotannins isolated from methanol extract of brown seaweeds *Sargassum polycystum* (IC50: 35*:*245 μg/ ml), Turbinaria Ornate (IC50: 22*:*7 μg/ml), and Padina pavonica IC50: 15*:*16 μg/ml) had the ability to suppress the formation of advanced glycation end-products [61]. Further, phlorotannins extracted from the ethyl acetate fraction of *Fucus vesiculosus* (IC50: 0.045 mg/ml) significantly inhibited the AGEs formation compared to the phloroglucinol (IC50: 0.068 mg/ml) [62].

## **b.Green seaweeds**

So far, minimal studies have been reported to demonstrate the inhibitory effect of green seaweeds on the formation of advanced glycation end products. The chloroform, ethanol, and butanol fractions of a green seaweed *Capsosiphon fulvescens* have been reported to exhibit an inhibitory effect on the formation of advanced glycation end-products [50].

### **c.Red seaweeds**

Regarding the red seaweeds, the ethyl acetate fraction (IC50: 586.54 μg/ml) of *Gracillaria edulis* has been reported to exhibit the inhibitory effect on the formation of advanced glycation end products compared to the standard drug rutin (IC50: 11.55 μg/ml) [34]. Similarly, carrageenan extract from red algae could inhibit progressive glycation end product uptake by macrophage-like RAW 264.7 cells [63].
